Article info

Download PDFPDF
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

Authors

  1. Correspondence to Dr José Alejandro Perez-Fidalgo, Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain; japfidalgo{at}msn.com
View Full Text

Citation

Perez-Fidalgo JA, Guerra E, García Y, et al
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

Publication history

  • Received October 17, 2022
  • Accepted January 25, 2023
  • First published February 9, 2023.
Online issue publication 
June 05, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.